Skip to main content
Veterinary Medicines

Credelio 225 mg - Chewable tablet (dogs)

Authorised
  • Lotilaner

Product identification

Medicine name:
Credelio 225 mg - Chewable tablet (dogs)
Active substance:
  • Lotilaner
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Lotilaner
    Presentation_strength:225 mg Reference:Hse Index:0
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53BE04
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Available in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
Package description:
  • Packaging:Blister (Alu/Alu), Package_size:3 tablets
  • Packaging:Blister (Alu/Alu), Package_size:1 tablet
  • Packaging:Blister (Alu/Alu), Package_size:6 tablets
  • Packaging:Blister (Alu/Alu), Package_size:18 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Elanco GmbH
Marketing authorisation date:
  • -
Manufacturing sites for batch release:
  • Elanco France S.A.S
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 22/02/2024
Download
Bulgarian (PDF)
Published on: 22/02/2024
Croatian (PDF)
Published on: 22/02/2024
Czech (PDF)
Published on: 22/02/2024
Danish (PDF)
Published on: 22/02/2024
Dutch (PDF)
Published on: 22/02/2024
Estonian (PDF)
Published on: 22/02/2024
Finnish (PDF)
Published on: 22/02/2024
French (PDF)
Published on: 22/02/2024
German (PDF)
Published on: 22/02/2024
Greek (PDF)
Published on: 22/02/2024
Hungarian (PDF)
Published on: 22/02/2024
Icelandic (PDF)
Published on: 22/02/2024
Italian (PDF)
Published on: 22/02/2024
Latvian (PDF)
Published on: 22/02/2024
Lithuanian (PDF)
Published on: 22/02/2024
Maltese (PDF)
Published on: 22/02/2024
Norwegian (PDF)
Published on: 22/02/2024
Polish (PDF)
Published on: 22/02/2024
Portuguese (PDF)
Published on: 22/02/2024
Romanian (PDF)
Published on: 22/02/2024
Slovak (PDF)
Published on: 22/02/2024
Slovenian (PDF)
Published on: 22/02/2024
Spanish (PDF)
Published on: 22/02/2024
Swedish (PDF)
Published on: 22/02/2024

ema-puar-credelio-v-4247-var-x-0001-en.pdf

English (PDF)
Published on: 22/03/2023
Download

ema-puar-credelio-v-4247-var-ii-0019-en.pdf

English (PDF)
Published on: 22/03/2023
Download

ema-puar-credelio-v-004247-par-en.pdf

English (PDF)
Published on: 9/08/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."